Market Overview

UPDATE: Paradigm Capital Lowers PT to $67 on Valeant Pharmaceuticals on Raising Interest Cost

Share:
Related VRX
Watch These 7 Huge Put Purchases In Thursday Trade
Benzinga's Option Alert Recap From April 26
Jones Collombin Investment Counsel Inc Buys Stantec, First Republic Bank, Amazon. ... (GuruFocus)

Paradigm Capital reiterated its Buy rating on Valeant Pharmaceuticals (NYSE: VRX) but lowered its price target from $70 to $67 ahead of the quarterly earnings release.

Paradigm Capital commented, "We continue to hold a positive view toward Valeant's unique approach to running a specialty pharmaceutical company, which we believe sets it apart from its peers. That said, the debt raised recently to pay for the Medicis acquisition leads to a material increase in interest payments, which dilutes the company's earnings power. We are lowering our price target to $67.00 (from $70.00) to account for these interest payments."

Valeant Pharmaceuticals closed at $54.62 on Tuesday.

Latest Ratings for VRX

DateFirmActionFromTo
Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Paradigm CapitalAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!